

SUBJECT INDEX

- A-65186, 779
 [³H]ACh binding, HCh-3 binding, 129
 ACh content, 129
 AChE inhibitor, 129
 Abuse liability, 303
 Acetylcholine, 207, 261
 Acetylcholinesterase, 805
 N-acetylneuraminic acid, 209
 Acetyl-salicylic acid, 325
 Active avoidance learning, 805
 Acute opioid dependence, 705
 Adenosine agonist, 507
 S-Adenosyl-L-methionine (SAM), 395
 Adenylate cyclase, 139
 Adjunctive drinking, 591
 Adrenalectomy and nicotine lethality, 559
 Adverse side-effects, 685
 Affective disorders, 207
 Aged rats, 805
 Aggression, 247
 Aggressive, 65
 Akathisia, 759
 Alarm pheromone, 213
 Alcohol, 201, 591
 Alcohol drinking, 381
 Alcohol intake, 201
 Alcohol-preferring rats, 381
 Alloxan, 511
 Alpha-1 receptors, 89
 Alpha-2 receptors, 89
 N-Allylnormetazocine, 405
 Ambivalent behaviors, 361
 Amino acid neurotransmitters, 905
 Amino acids, 107, 829
 1-Aminocyclopropanecarboxylic acid, 313
 Amnesia, 439
 Amotivational syndrome, 871
 Amphetamine, 165, 289, 545, 739, 863, 923
d-Amphetamine, 65, 187, 297, 609, 791
 (+)-Amphetamine, 465
 Amphibians, 753
 Analgesia, 83, 317, 413, 425, 497, 911
 Angiotensin II, 201
 Angiotensin converting enzyme inhibitor, 685
 Animal model of depression, 691
 Anorexia, 17, 317, 717, 797
 Anterior nucleus accumbens, 157
 Anticholinergic, 303
 Antihypertensive agents, 685
 Antinociception, 511
 Antipsychotic drug, 759
 Antitussive drugs, 595
 Anxiety, 931
 Anxiogenic drug, 785
 Anxiolytic agents, 293
 Anxiolytic response, 1
 Anxiolytics, 313
 Apomorphine, 59, 345, 545, 673, 915, 923
 Appetite, 433
 Atropine, 303
 Attention, 823
 Aversive behavior, 769
 Avoidance, 585
 BALB mouse, 165
 Baboons, 685
 Baclofen, 491
 Barbiturate, 399
 Barbiturate anesthesia, 727
 Bay-K-8644, 325
 Behavior, 181, 303, 337, 473, 863
 Behavioral alterations, 229
 Behavioral effects, 609
 Behavioral pharmacology, 297, 609
 Behavioral sensitization, 345
 Behavioral tests, 839
 Benzodiazepine, 37, 399, 585, 733, 839
 Benzodiazepine receptors, 711
 Beta-adrenergic receptor, 603
 Beta-adrenoceptors, 247
 Biochemistry, 473
 Biogenic amines, 223
 Blood glucose, 791
 Blood Δ^9 -THC and COHb saturation from marijuana smoke, 521
 Blood pressure, 349, 685
 Body rotation, 317
 Body temperature, 375
 Body temperature by radio telemetry, 241
 Brain, 355
 Brain 5-HT receptors, 275, 283
 Brain areas, 341
 Brain dopamine, 577
 Brain liquification, 77
 Brain self-stimulation, 23, 785
 Brain serotonin, 577
 Brain slices, 571
 Bremazocine, 753
 Brightness discrimination, 209
 Buspirone, 349
 Butorphanol, 847
 cAMP, 665
 CBA/Ca mice, 255
 C \times B recombinant inbred strains, 733
 CCK, 779
 CCKA receptors, 157
 CCK-8, 95, 779
 CGS 8216, 585
 ChAT, 129
 CL218872, 711
 CPP, 739
 C3H mouse, 165
 C57 mice, 165, 331
 C57BL/6J mice, 241
 Caerulein, 95
 Cafeteria rat, 341, 577
 Caffeine, 483, 565
 Calcium, 73
 Calcium gluconate, 73
 Carbohydrate, 829
 β -Carboline, 733
 β -Carboline-3-carboxylate-*t*-butyl ester, 37
 Cardiovascular, 565, 631
 Cardiovascular effects, 405, 697
 Catechol estrogens, 459
 Catecholamines, 349, 565
 Catheterized, 349
 Cathinone, 289
 Caudate nucleus, 367
 Central morphine analgesia, 119
 Chicken embryos, 705
 Chicks, 439
 Chlordiazepoxide, 313, 711, 931
 Chlordiazepoxide dependence, 839
 7-Chlorokynurenic acid, 313
 Chloroquine, 77
 Chlorpromazine, 1, 585
 Choice, 297
 Cholecystokinin, 779
 Cholecystokinin octapeptide, 157, 387
 Cholecystokinin octapeptide unsulfated, 157
 Choline acetyltransferase, 805
 Cholinergic, 207, 261
 Cholinergic supersensitivity, 691
 Cigarettes, 565
 Cinnarizine, 325
 Circadian, 533
 Circadian rhythms, 465
 Circumventricular organ, 201
 Cleft palate, 77
 Climbing, 95
 Clonidine, 413, 433
 Clonidine aggressive behavior, 503
 Cocaine, 165, 289, 655, 697, 887, 899
 Coffee, 565
 Cognitive enhancement, 649
 Cognitive tasks, 173
 Cold-water swim, 83
 Color discrimination, 685
 Computer, 919
 Concurrent schedule, 297
 Conditioned drug effects, 663
 Conditioned position responding, 29
 Conditioning, 59, 655
 Continuous cold-water swims, 511
 Control of ventilation, 681
 Corticosterone, 247
 Corticotropin-releasing factor, 517
 Cortisol, 747
 Cough reflex, 595
 Cumulative dose-effect curves, 855
 D₁, 43
 D₁-agonist, 367
 D₂, 43
 D₂-antagonist, 355, 367
 D1 receptors, 337, 923
 D2 receptor, 453, 923
 DBA mouse, 165
 DFP, 473
 DNA, 77
 DSLET, 577
 Delayed matching to sample, 29
 Depression, 207
 Desmethylimipramine, 915
 Development, 367, 721, 727
 Developmental neurotransmitters, 229
 Diabetes, 255, 511
 Diazepam, 1, 23, 29, 609, 769
 Dichloromethane, 619
 Discrete trial, 297
 Discriminative stimulus properties, 23
 Diterpine, 503

- Dogs, decerebrated, 405
Dopamine, 59, 95, 113, 165, 289, 337, 341, 345, 367, 453, 571, 727
Dopamine antagonists, 43
Dopamine development, 545
Dopamine D₁/D₂ receptors, 465
Dopamine receptors, 139, 721
Dorsal immobility response, 459
Dose response, 697
Down regulation, 247
Drug, 303
Drug abuse, 609
Drug discrimination, 289, 337, 429, 571, 641, 711
Drug effects, 29
Drug history, 149
Drug self-administration, 149
Drug-induced compensatory learning, 855
Dynorphin (1-13), 577
Dyskinesia, 95, 193, 759
Dystonia, 759
- EEG, 619, 631
EGTA, 73
E. coli endotoxin, 325
Eating, 631
Electroencephalogram, 507
Elevated plus-maze, 931
Emotionality, 157, 197, 361
Enalapril maleate, 685
Endogenous opioids, 681
 β -Endorphin, 577
Energy expenditure, 765
Energy substrate utilisation, 765
Enrichment, 487
Entactogens, 571
Epinephrine, 247
Escape task, 439
Estradiol, 89, 459
Estrous phases, 119
Ethanol, 77, 201, 247, 321, 331, 399, 487, 585, 855, 905
Ethanol antagonism, 399
Ethanol lethality, 375
Ethanol stimulation, 331
Ethylketazocine, 405
Etonitazene, 419
Event-related potentials, 631
Excitatory amino acids, 101
Excitotoxic lesions, 139
Exogenous gangliosides, 209
Expectancy, 149
Exploration, 157
Exploratory behavior, 517
Exteroceptive stimulus control, 641
Extinction, 585, 591
- FMRF-amide, 341
FR-40 disruption, 275, 283
FSL rats, 691
Fasting, 791
Feeding, 433, 911
Feeding behavior, 539
Fenoldopam, 17
Fentanyl, 419
Fetal striatal tissue grafts, 139
Fetus, 77
Fixed interval:15 second schedule, 785
Fixed ratio:15 schedule, 785
Flumazenil (Ro 15-1788), 399
Fluoxetine, 381
- Food deprivation, 791
Food intake, 341, 577, 717, 797
Forced inhalation of marihuana smoke, 521
Forskolin, 139, 665
Frontal cortex, 805
- GABA, 237, 905
GABA_A receptors, 237
GABA_B receptors, 237
GABA motor impairment, 399
Galanthamine, 129
Gender differences, 119
Genetic analysis, 733
Genetics, 905
Glucose, 631
Glycine, 313, 491, 823
Glycine receptor, 649
Gonadectomy, 119
Guinea pig, 89
Guinea pig ileum assay, 527
- HPA axis, 747
HPLC, 545
5-HT agonist, 275, 283
5-HT receptors, 603, 717
5-HT-dependent behavior, 603
5-HT_{1A} and 5-HT_{1B} receptor subtypes, 811
5-HT_{1A} receptors, 927
5-HT₃ receptor antagonist, 769
Haloperidol, 95, 113, 345, 721, 727
Hamster, 387
Heart rate, 349
Hepatomegaly, 77
Hexamethonium, 817
Hexamethonium prevention of nicotine lethality, 559
High-affinity choline uptake, 553
Hippocampus, 553, 805
Hot-plate test, 497
Human behavioral pharmacology, 173
Human speech, 609
Human study, 303
Humans, 65, 297, 697, 791, 871
6-Hydroxydopamine, 367, 413, 663
5-Hydroxytryptamine (5-HT), 165, 603, 717, 829
8-Hydroxy-2-(di-N-propylamino) tetralin, 381
Hyperglycemia, 511
Hypophysectomy, 517
Hypothalamus, 879
Hypothermia, 1, 241
- ICV administration, 325
Idazoxan, 89
Imipramine, 275
Impairment, 303
Inbred strains of mice, 375
Inbred strains of mice (BALB/cBy and C57BL/6By), 733
Inclined plane, 1
Incremental repeated acquisition, 29
Indirect calorimetry, 765
Ingestion, 919
Ingestive behavior, 387
Inhibition of RNA, 77
Inhibition of amine uptake, 165
Inhibitory amino acids, 491
Instructions, 149
Insulin, 539, 631, 765
Intake, 487
Interdrug associations, 1
- Interoceptive stimulus control, 641
Intoxication, 905
Intrathecal administration, 491
Intrathecal morphine, 265
Intrathecal space, 107
Inverse agonist, 37, 733
In vivo catecholamine release, 879
Ipsapirone, 811, 927
Isobutylmethylxanthine, 705
Isocarboxazid, 283
Isolation stress, 915
Isolation-induced timidity, 361
Isoniazid, 399
Itch, 491
- K-function, 863
Ketone bodies, 791
- LSD, 571
LY 171555, 43, 193
LY163502, 453
Lateral preoptic area, 101
Learning, 29, 181
Learning and memory, 209, 649, 663
Lesions, 663
Lever-pressing, 275, 283
Levodopa, 193
Lick detectors, 419
Lidocaine, 887
Liquid diet, 919
Lithium, 591
Local anesthetics, 887
Locomotion, 739, 753, 779
Locomotor, 413
Locomotor activity, 101, 331, 345, 465, 507, 545, 785, 887
Lofexidine, 433
Long-term potentiation, 13
Lordosis, 665
Lordosis behavior, 89
Lumbricus, 213
- MAO-B, 823
mCPP, 811
MDA, 571
MDMA, 223, 497, 571
MK-801, 13
MPP⁺, 545
MPTP, 113, 545
MSLT, 321
Male sexual behavior, 53
Marihuana, 173, 521, 871
Maternal behavior, 83
Maturation, 413
Mecamylamine, 817
Mecamylamine prevention of nicotine lethality, 559
Medial preoptic area, 453
Memory, 29, 181, 823
Mental retardation, 759
Meperidine, 429
Methadone, 705
5-Methoxy-N,N-dimethyltryptamine (5-MeODNT), 603
N-methyl-D-aspartate receptors, 313
N-Methyl-4-phenyl-1-1,2,3,6-tetrahydropyridine (MPTP), 193
Methyl β -Carboline-3-carboxylate (β -CCM), 733
Mice, 17, 113, 129, 293, 317, 361, 553, 769, 779
Microdialysis, 899

Midazolam, 439
 Midbrain central gray, 665
 Milacemide, 823
 Monetary reinforcement, 297
 Monkeys, 29, 193, 433
 Monoamine metabolism, 355
 Monoamine metabolites, 341
 Morphine, 83, 241, 361, 425, 429, 511, 705, 847, 911, 919
 Morphine analgesic tolerance, 265
 Morphine dependence, 595
 Morphine tolerance, 445
 Morphine tolerance-dependence, 7
 Motion sickness, 317
 Motivation, 871
 Motor behavior, 685
 Motor disturbances, 673
 Mouse-killing behavior, 395
 Movement disorder, 759
 Multiple T-maze learning, 805
 Muricide, 879
 Muscarinic, 207
 Muscle relaxation, 1
 Muscular dystrophy, 681
 Mycotoxin, 229
 Myocardium, 247

 NAN-190, 927
 nBM lesion, 129
 NMDA, 181, 739
 NMDA receptor, 13, 649, 823
 NMDA receptor antagonist, 739
 N-0437, 17
 N⁶-(L-2-phenylisopropyl)-adenosine (L-PIA), 507
 Naloxone, 197, 317, 425, 539, 753, 911
 Naloxone-induced analgesia (NIA), 197, 425
 Naloxone-precipitated withdrawal, 7
 Naltrexone, 577
 Naltrexone prevention of nicotine lethality, 559
Nerodia, 95
 Neuroleptics, 95, 293, 655
 Neurotoxicity, 223
 Nicotine, 149, 261, 559, 565, 817
 Nicotine's respiratory depressant actions in the rat, 559
 Nicotinic receptor, 817
 Nifedipine, 325, 915
 Nociception, 911
 Nonhuman primates, 685
 Noradrenergic activity, 931
 α -Noradrenergic antagonist, 553
 Noradrenergic transmission, 89
 Norepinephrine, 165, 247, 413
 Nucleus accumbens, 101, 739, 899
 Nursing mice, 229

 Obesity, 255
 Olfactory bulbectomy, 395, 879
 Ondansetron, 769
 One trial learning, 663
 Operant, 65
 Operant behavior, 29, 641, 923
 Operant performance, 855
 Operant responding, 927
 Opiate analgesic synergy, 265
 Opiate receptors, 425
 Opiates, 83, 419, 753
 Opioid receptors, 847
 Opioid withdrawal, 705
 Opioidergic and nicotinic processes: nicotine lethality, 559
 Opioids, 83, 241
 Oral movement, 43
 Oral self-administration, 419
 Organophosphates, 473
 Oxotremorine, 207
 Oxytocin, 673

 Pain, 119, 911
 Pain responses, 511
 Parity, 83
 Parkinsonism, 193, 759
 Parkinson's Disease, 545
 Passive avoidance, 181, 439
 Pattern recognition, 863
 Penile erection, 453, 673
 Pentobarbital, 23, 49, 669, 915
 Performance, 303, 321, 871
 Performance effects, 173
 Periaqueductal gray, 265
 Pharmacological responses, 847
 Phenelzine, 283
 Phenoxybenzamine, 553
 Phenylethylamines, 797
 Phenylpropanolamine, 187
 Phorbol ester, 665
 Physical dependence, 49, 241, 919
 Physostigmine, 915
 Picrotoxin, 399
 Pigeons, 59, 641
 Pituitary, brain regions, 7
 Placebo, 261
 Plasma glucose, 255
 Plus-maze, 1, 313
 Polydipsia, 691
 Position preference, 419
 Position responding, 641
 Postejaculatory vocalization, 53
 Postero-median nucleus accumbens, 157
 Potassium stimulation, 107
 Prazosin, 89
 Preference, 297
 Prenatal drug effects, 721, 727
 Prenatal-postnatal exposure, 229
 Progesterone, 89
 Progressive ratio, 29
 Prolactin, 83
 Protein, 829
 Protein kinase C, 665
 Protein metabolism, 77
 Psychomotor, 303
 Psychomotor stimulants, 655
 Psychomotor tasks, 173
 Puffing behavior, 631
 Push-pull perfusion, 879
 Push-pull superfusion, 107

 QNB binding, 129
 Quasiopioid withdrawal, 705
 Quinelorane, 453

 REM, 37, 507
 RO 15-1788, 197, 585, 839
 RO 15-4513, 23, 585, 785
 RU 24969, 811
 Rabbit, 325, 433
 Radial arm maze, 13, 599
 Radioimmunoassay, 747
 Raphe lesions, 395
 Rapid information processing, 631
 Rat, 17, 49, 53, 119, 157, 181, 207, 209, 261, 337, 345, 349, 355, 387, 429, 465, 511, 533, 585, 599, 619, 711, 765, 769, 817, 855, 863, 919
 Rat masculine sexual behaviour, 811
 Rat vas deferens assay, 527
 Rats, female, 491
 Receptors, 207, 261
 Recreational activity, 871
 Reference memory, 599
 Regional superfusion, 107
 Reinforcement, 59, 149, 899
 Renin-angiotensin system, 201
 Renovascular hypertension, 685
 Respiratory effects, 405
 Respiratory quotient, 765
 Responses to hypercapnia, 681
 Resting behavior, 387
 Restraint stress, 517
 Reuptake, monoamine, 887
 Rhesus monkeys, 521, 669
 Ritanserin, 533
 Rotation, 663
 Rotation behavior, 139

 SCH 23390, 43, 113, 337, 367
 SKF 38393, 17, 43, 367
 SKF 38393-inducible RJM in control and EEDQ-treated rats, 895
 SK&F 75760, 17
 Saliva, 483, 747
 Satiety, 829
 Sclareol glycol, 503
 Scopolamine, 599
 Scratching, 491
 Secalonic acid, 229
 Secobarbital, 609, 669
 Sedation, 507
 Seizures, 733
 Seizures, cocaine-induced, 887
 Seizures, lidocaine-induced, 887
 Selected lines, 399, 905
 Selected lines of mice, 375
 Selective dopamine receptor agonists and antagonists, 53
 Self-administration, 187, 669, 899
 Seminal emission, 453
 Sensitization, 59, 465, 655
 Sensorimotor behavior, 113
 Sensory-evoked potentials, 619
 Sensory stimulation, 107
 Septum, 553
 Serotonin, 341, 367, 413, 497, 571
 Serotonin hyperinnervation, 367
 Serotonin receptors, 595
 Serotonin syndrome, 367
 Serum insulin, 255
 Serum triglycerides, 255
 Sexual behavior, 89
 Sham lesion, 915
 Shock, 591
 Sleep, 37, 507, 533
 Sleepiness, 321
 Smoking, 149, 631
 Smoking topography, 173
 Social behavior, 609
 Social behavioral deficit, 293
 Social interaction, 297
 Solvent abuse, 619
 Soman, 473
 Spatial navigation, 129
 Spinal cord, 107
 Spinal opiate antinociception, 445
 Spinal rats, 445

Spiroxitrine, 381
 Stereoisomers, 669
 Stereotypy, 545, 727
 Stress, 207, 261, 317, 349
 Stress adaptation, 603
 Stress-induced analgesia, 197
 Stress ulceration, 73
 Striatum, 139, 459
 Structure-activity relationship, 527
 Subfornical organ, 201
 Subjective effects, 173, 697, 791
 Substance P, 491, 527
 Substance P receptors, 527
 Substantia innominata, 101
 Sucrose, 911
 Sulpiride, 43, 113
 Supersensitivity, 113, 545
 Sweeteners, 483
 Symbolic, matching-to-sample, 641

T₄, T₃, T₃U, TSH, 7
 TFMPP, 811

THC, 173
 TRH, 95
 TRH receptors, 7
 Tail flick, 265
 Tail-flick test, 497
 Tail-tremor, 817
 Taste, 419, 483
 Taurine, 491
 Telemetry, 261
 Temporal response differentiation, 29
 Test battery, 29
 Thermogenesis, 765
 Thermoregulation, 241, 261, 325, 539
 Thyroid hormones, 7
 Time-course, 289
 Tizanidine, 433
 Tobacco, 149
 Tolerance, 59, 149, 331, 465, 473, 855, 911
 Trazodone, 275
 Triglycerides, 631
 Tryptophan, 829
 Type A CCK receptors, 779

Vacuuous chewing movement, 43
 Vasoactive intestinal peptide, 387
 Vasopressin, 673
 Verapamil, 73, 325

Wakefulness, 533
 Water intake, 797
 Weight gain, 691
 Withdrawal, 911, 931
 Withdrawal signs, 839
 Withdrawal syndrome, 49, 241
 Working memory, 13, 553, 599

Xenopus skin mucus, 95
 Xenopsin, 95
 Xylamidine, 717

YM-09151-2, 355
 Yawning, 95, 237, 673, 915

AUTHOR INDEX

Advokat, C., 265, 445
 Ågmo, A., 811
 Ali, S. F., 721, 727
 Alkana, R. L., 375
 Alvarez, W. F., 759
 Araki, Y., 817
 Argioli, A., 673
 Arnolde, S. M., 823
 Asai, S., 355
 Atrens, D. M., 765

Babbini, M., 429
 Babcock, A. M., 539
 Bacchi, A., 429
 Baldwin, H. A., 931
 Banas, C., 491
 Bansinath, M., 7
 Barfield, R. J., 53
 Barthalmus, G. T., 95
 Bartoletti, M., 429
 Barton, C., 539
 Baruch, N. P., 663
 Bättig, K., 631
 Beau, N., 157
 Bejanian, M., 375
 Belknap, J. K., 241
 Benarroch, A., 487
 Beninger, R. J., 923
 Benowitz, N. L., 565
 Berman, K. F., 507
 Bernstein, D. J., 871
 Berridge, C. W., 517
 Bettin, M. A., 317
 Beyer, C., 491
 Bhargava, H. N., 7
 Bickel, W. K., 297
 Bitran, D., 453
 Blundell, J. E., 829
 Bodnar, R. J., 119, 511
 Boggan, W. O., 331
 Boja, J. W., 497
 Bolon, B., 229
 Bostwick, M., 559
 Bosity, T. Z., 165

Bourson, A., 915
 Brady, J. V., 871
 Brake, L. D., 1
 Breese, G. R., 367
 Bridges, R. S., 83
 Britton, D. R., 779
 Bronson, M. E., 705
 Brown, C. R., 565
 Bruno, J. P., 113
 Burg, B., 59
 Burris, K., 571
 Butelman, E. R., 13

Cagiano, R., 53
 Calderon, S. F., 545
 Cappell, H., 197, 425
 Carelli, R. M., 739
 Carlson, K. R., 419
 Castellano, C., 361
 Chan, A. W. K., 839
 Chapouthier, G., 733
 Cherek, D. R., 65
 Cho, C. H., 73
 Cohen, Y., 341, 577
 Collins, A. C., 887
 Connelly, D. M., 255
 Cook, J. M., 37
 Cook, V. I., 387
 Cooper, M. L., 119
 Cooper, S. J., 17
 Cordi, A. A., 649, 823
 Costall, B., 769
 Cottrell, G. A., 459
 Coyle, J. T., 129
 Crisp, T., 497
 Criswell, H. E., 367
 Cullen, M. J., 779
 Cuomo, V., 53

D'Amato, F. R., 361
 Das, S., 7
 Daugé, V., 157
 Dave, V., 275
 Deans, C., 927

de Fiebre, C. M., 887
 Delius, J. D., 59
 DeNoble, V. J., 181
 Derrien, M., 157
 Desforges, C., 733
 Deviche, P., 753
 de Wit, H., 791
 Dilsaver, S. C., 207, 261
 Dodd, R. H., 733
 Doger, E., 237
 Double, K., 691
 Doyle, J. S., 387
 Dugovic, C., 533
 Dunn, A. J., 517
 Durkin, T., 553

Edwards, S., 717
 Eguibar, J. R., 237
 El-Etri, M. M., 545
 Ellman, G., 759
 Eriksson, P. S., 919
 Escalante, A., 811

Favara, J. P., 331
 Feder, H. H., 89
 Féger, J., 157
 Fenwick, J. W., 149
 Fernandez-Guasti, A., 811
 File, S. E., 931
 Finn, D. A., 375
 Fischman, M. W., 871
 Flemmer, D. D., 207, 261
 Foderaro, M. A., 387
 Foltin, R. W., 871
 Frances, H., 293
 Friedhoff, A. J., 895
 Fujiwara, M., 879
 Furuno, K., 817

Gaiardi, M., 429
 Galizio, M., 585
 García-Antón, J. M., 527
 Gardner, C. R., 711
 Geary, N., 797

Georgieva, J. V., 503
 Gessa, G. L., 673
 Gibson, J. E. M., 487
 Gilbert, D. B., 439
 Giordano, M., 139
 Glazner, G. W., 387
 Gomita, Y., 817
 Gonzalez-Flores, O., 491
 Goudie, A., 927
 Goudreau, J., 283
 Gough, B. J., 721
 Grupp, L. A., 201
 Gubellini, C., 429
 Gulliver, S. B., 149

Haase, C., 59
 Hadjiconstantinou, M., 113
 Hagen, T. J., 37
 Halpern, M., 213
 Hamm, M. W., 247
 Handelmann, G. E., 649, 823
 Haro, I., 527
 Harris, N., 349
 Hasenfratz, M., 631
 Heishman, S. J., 173
 Hellevo, K., 399, 905
 Hellhammer, D. H., 747
 Henningfield, J. E., 303
 Hienz, R. D., 685
 Higgins, S. T., 149, 297
 303, 609
 Hines, G., 591
 Hitchcott, P. K., 931
 Ho, I. K., 847
 Hoffman, A. J., 571
 Hoffman, D. C., 923
 Holloway, F. A., 855
 Holmgren, B., 237
 Holson, R. R., 721, 727
 Hood, W. F., 649
 Hopper, D. L., 863
 Horan, P. J., 847
 Hughes, J. R., 149, 297
 Hull, E. M., 453